Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.
Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Rajca S, et al. Among authors: louis e. Inflamm Bowel Dis. 2014 Jun;20(6):978-86. doi: 10.1097/MIB.0000000000000036. Inflamm Bowel Dis. 2014. PMID: 24788220 Clinical Trial.
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Among authors: louis e. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Among authors: louis e. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
Willot S, Vermeire S, Ohresser M, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Franchimont D, Colombel JF, Watier H, Louis E. Willot S, et al. Among authors: louis e. Pharmacogenet Genomics. 2006 Jan;16(1):37-42. doi: 10.1097/01.fpc.0000182776.57437.d8. Pharmacogenet Genomics. 2006. PMID: 16344720
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis.
Daniel F, Loriot MA, Seksik P, Cosnes J, Gornet JM, Lémann M, Fein F, Vernier-Massouille G, De Vos M, Boureille A, Treton X, Flourié B, Roblin X, Louis E, Zerbib F, Beaune P, Marteau P. Daniel F, et al. Among authors: louis e. Inflamm Bowel Dis. 2007 Jan;13(1):19-23. doi: 10.1002/ibd.20046. Inflamm Bowel Dis. 2007. PMID: 17206635 Free article.
1,582 results